Small Animal Containment

由于嵌合小鼠模型领域的突出进展和重要发展 与人类免疫系统和细胞重组，核心H，小动物生物防护（ABC）核心 扩大了范围，现在包括两个地点。研究中心A位于马萨诸塞州总医院 (MGH)和站点B是Dana-Farber癌症研究所（DFCI）现有的BL-3 ABC设施。 研究中心A将提供以下服务： 1.产生人源化BLT小鼠（移植有人胎儿胸腺、肝脏和胸腺的NOD-SCID-Hu小鼠）。 造血干细胞（HSC）），供CFAR研究人员用于实验，将在 转移后，本核心的MGH或DFCI研究中心，或合作研究者的研究中心 BLT小鼠到他/她的动物设施。 2. BLT小鼠外周血白细胞的出血和流式细胞术以表征其人类 在使用前由合作研究者进行免疫重建。 3.对于选择在MGH现场进行实验的合作研究者， HIV感染小鼠的处理和分析。 4.对于选择在自己的动物设施中进行实验的合作研究人员， 安全处理感染艾滋病毒的老鼠。 5.产生的人病毒特异性细胞和体液免疫应答的进一步表征 在HIV感染的BLT小鼠中，扩大了这一模型可以支持的研究领域。 研究中心B将提供以下服务： 1.使用动物设施，防止传染性病原体在动物之间传播。 2.在处理可能感染人类或动物的动物方面提供技术支持。 3.获得将HIV-1接种到嵌合BLT或NOG中的技术支持（即， IL-2 R γ 1）小鼠，将其圈养以评估 候选抗病毒剂在这些新的小动物模型中的功效和毒性。一个特殊的加 部位B是允许结核分枝杆菌（MT B）或HIV-1/MT B合并感染工作的能力。 4.使用安全的工作条件。 5.在小动物模型中安全处理潜在人类病原体的培训。

Due to outstanding progress and important developments in the field of chimeric mouse models reconstituted with human immune systems and cells, Core H, the Small Animal Biocontainment (ABC) Core expanded its scope and now includes two sites. Site A is located at the Massachusetts General Hospital (MGH), and Site B is the existing BL-3 ABC Facility at the Dana-Farber Cancer Institute (DFCI). Site A will provide the following services: 1. Generation of humanized BLT mice (NOD-SCID-Hu mice transplanted wit human fetal thymus, liver and hematopoietic stems cells (HSC)) for CFAR investigators to use for experiments, to be performed at the MGH or DFCI Sites of this core, or at the site of the collaborating investigator, following transfer of the BLT mice to his/her animal facility. 2. Bleeding and flow cytometry of peripheral blood leukocytes of the BLT mice to characterize their human immune reconstitution prior to use by collaborating investigators. 3. For collaborating investigators choosing to perform their experiments at the MGH site, support in the handling and analysis of HIV-infected mice. 4. For collaborating investigators choosing to perform experiments in their own animal facilities, training in the safe handling of HIV-infected mice. 5. Further characterization of the human virus-specific cellular and humoral immune responses generated in HIV-infected BLT mice, to expand the areas of investigation this model can support. Site B will provide the following services: 1. The use of an animal facility in which the spread of contagious agents is prevented between animals. 2. Technical support in handling animals potentially infectious to humans or animals. 3. Access to technical support for performing HIV-1 inoculations into chimeric BLT or NOG (i.e., NOD/SCID.IL-2RYNull) mice reconstituted with CD34+ human HSC, which will be housed to evaluate candidate antiviral agents for efficacy and toxicity in these novel small animal models. A special plus of Site B is the ability to permit work with Mycobacterium tuberculosis (MTb) or HIV-1/MTb co-infections. 4. The use of safe working conditions. 5. Training for safe handling of potential human pathogens in small animal models.